CDC's Shocking New Grant: What They Discovered About Hepatitis B Vaccination in Guinea-Bissau Will Leave You Speechless!

The Centers for Disease Control and Prevention (CDC) has granted approximately $1.6 million to the University of Southern Denmark (SDU) for a significant randomized clinical trial that aims to evaluate the health impacts of neonatal monovalent hepatitis B vaccination in Guinea-Bissau. This grant, awarded non-competitively, will span a period of five years, from January 5, 2026, to January 4, 2031, and will fund a single-blind, multicenter, phase 4 randomized controlled trial involving more than 14,000 newborns.

The primary focus of this study is to assess the effects of administering the hepatitis B virus (HBV) vaccine at birth on various health outcomes, including all-cause mortality, severe morbidity, and long-term neurodevelopmental effects. Additionally, the trial will investigate potential sex-specific differences in the efficacy of the vaccine.

Conducted in Guinea-Bissau, a low-income country, this research aligns with the World Health Organization's (WHO) recommendations for administering three vaccines at birth: Bacille Calmette-Guérin (BCG), oral polio vaccine (OPV0), and the hepatitis B vaccine. While the benefits of BCG and OPV in promoting child health have been documented, the CDC acknowledges that data on the non-hepatitis-specific health benefits of the HBV vaccine is sparse, prompting the need for this comprehensive evaluation.

The CDC's decision to award the grant to SDU is rooted in the university's extensive experience leading vaccine trials in West Africa, along with its established partnerships with local hospitals and health authorities in Guinea-Bissau. Previous research by SDU in neonatal and pediatric health in low-resource settings further solidified its qualifications for this study. Importantly, the CDC noted that there were no current or planned funding opportunities that would allow other institutions to compete for this grant.

The Ongoing Debate Over Vaccine Efficacy

This trial enters a contentious scientific debate concerning the non-specific effects (NSEs) of vaccines—defined as health outcomes that extend beyond the vaccines' intended protective effects against specific pathogens. Much of the existing evidence supporting NSEs has been derived from studies connected to the Bandim Health Project, overseen by researchers Christine Stabell Benn and Peter Aaby. A recent analysis published in the journal *Vaccine* highlighted that Bandim Health Project researchers contributed to about 35% of all clinical studies on NSEs indexed in Web of Science, excluding review articles.

However, the reliability of the evidence from these studies has come under scrutiny. A reanalysis led by Henrik Støvring, PhD, and colleagues critically examined randomized controlled trials from the Bandim Health Project, following Danish media reports that raised concerns about research practices. Their review encompassed 40 published papers, focusing on 26 trials registered with ClinicalTrials.gov. They found significant methodological issues, including an emphasis on secondary outcomes that lacked statistical significance after appropriate adjustments, alongside concerns over unpublished primary outcomes and underpowered sample sizes.

Experts have voiced skepticism about the ethical and scientific justification for conducting additional studies on the hepatitis B vaccine, given the robust safety and efficacy data already available. Angela Rasmussen, PhD, expressed that the non-competitive nature of the grant appeared to reflect "blatant cronyism," while Amesh A. Adalja, MD, criticized the allocation of limited research funding for what he views as an unnecessary study.

As this trial proceeds, its findings are anticipated to contribute valuable evidence to the ongoing discourse regarding the effects of neonatal hepatitis B vaccination, particularly in understanding health outcomes beyond the prevention of hepatitis B virus infection. The implications of these results could markedly influence global immunization policy and practice, especially as they relate to the broader health consequences of administering the hepatitis B vaccine at birth.

References

1.CDC. Notice of Award of a Single Source Unsolicited Grant to Fund University of Southern Denmark (SDU). December 18, 2025. Accessed December 19, 2025. https://public-inspection.federalregister.gov/2025-23245.pdf

2.Støvring H, Ekstrøm C, Schneider J, Strøm C. What is actually the emerging evidence about non-specific vaccine effects in randomized trials from the Bandim Health Project? ScienceDirect. November 27, 2025. Accessed December 19, 2025. https://doi.org/10.1016/j.vaccine.2025.127937

3.Szabo L. CDC awards $1.6 million for hepatitis B vaccine study by controversial Danish researchers. CIDRAP. December 18, 2025. Accessed December 19, 2025. https://www.cidrap.umn.edu/childhood-vaccines/cdc-awards-16-million-hepatitis-b-vaccine-study-controversial-danish-researchers